BR100 Increased By (0.77%)
BR30 Increased By (0.87%)
KSE100 Increased By (0.78%)
KSE30 Increased By (0.83%)
AGHA 6.45 Increased By ▲ 0.07 (1.1%)
BECO 4.37 Increased By ▲ 0.02 (0.46%)
BML 62.83 Increased By ▲ 0.28 (0.45%)
BOP 31.47 Increased By ▲ 0.08 (0.25%)
CNERGY 11.79 Increased By ▲ 0.06 (0.51%)
CSIL 5.80 Decreased By ▼ -0.11 (-1.86%)
FCCL 61.70 Decreased By ▼ -0.01 (-0.02%)
FFL 15.00 Increased By ▲ 0.21 (1.42%)
FNEL 1.29 Increased By ▲ 0.05 (4.03%)
KEL 6.33 Increased By ▲ 0.01 (0.16%)
KOSM 5.80 Decreased By ▼ -0.10 (-1.69%)
LOTCHEM 24.90 Increased By ▲ 0.21 (0.85%)
MLCF 105.80 Increased By ▲ 1.87 (1.8%)
NBP 174.65 Increased By ▲ 1.33 (0.77%)
NCPL 52.14 Increased By ▲ 0.31 (0.6%)
NPL 54.77 Increased By ▲ 0.74 (1.37%)
OGDC 318.21 Increased By ▲ 2.34 (0.74%)
PACE 9.30 Increased By ▲ 0.04 (0.43%)
PAEL 35.82 Increased By ▲ 0.24 (0.67%)
PIBTL 14.23 Increased By ▲ 0.57 (4.17%)
PPL 229.01 Increased By ▲ 2.94 (1.3%)
PRL 81.45 Increased By ▲ 1.17 (1.46%)
PTC 46.92 Increased By ▲ 0.28 (0.6%)
SSGC 23.99 Increased By ▲ 0.17 (0.71%)
TBL 9.25 Increased By ▲ 0.01 (0.11%)
TELE 7.65 Increased By ▲ 0.10 (1.32%)
TPL 24.85 Increased By ▲ 0.31 (1.26%)
TPLP 12.93 Decreased By ▼ -0.06 (-0.46%)
TREET 25.92 Decreased By ▼ -0.06 (-0.23%)
TRG 53.79 Increased By ▲ 0.46 (0.86%)
World

Sanofi-GSK Covid booster jab shows positive results

Published Updated
By

PARIS: French drug maker Sanofi said Monday a Covid booster shot it is developing with Britain’s GlaxoSmithKline has produced positive results against Omicron and other variants in clinical trials.

The “next-generation” vaccine delivered a “strong immune response” against multiple variants of concern in two trials, Sanofi said in a statement.

The results are a boost for Sanofi and GSK, which have lagged behind rivals in offering a Covid vaccine.

Their candidate vaccine produced a 40-fold increase in antibodies against the BA.1 Omicron variant in adults who were given mRNA shots, the technology used by Pfizer-BioNTech and Moderna, Sanofi said.

It also generated a “higher immune response” than the Pfizer-BioNTech booster shot, the French company said.

China reports 275 new COVID cases for June 11 vs 210 a day earlier

The firms are combining a Sanofi-developed antigen, which stimulates the production of germ-killing antibodies, with GSK’s adjuvant technology, a substance that bolsters the immune response triggered by a vaccine.

“Covid-19 keeps evolving and the combination of emergence of variants and waning immunity is likely to lead to the need for additional booster shots, at least in some populations,” said Sanofi Vaccines executive vice president Thomas Triomphe.

“We believe this next-generation booster could have an important role to play for public health vaccination campaigns,” Triomphe said.

Sanofi and GSK are developing the next-generation jab at the same time that they are waiting for regulatory approval for their first-generation vaccine.

Comments

Comments are closed for this article.